Currently, there are several clinical trials testing CAR-T cells in AML, mostly targeting CLL1, CD123, and CD33, that are all myeloid antigens overexpressed in leukemic blasts but also in their normal stem cell counterpart; however, various other myeloid antigens (e.g., CD64, CD13, CD93, and CD38) as well as repurposed lymphoid antigens (e.g., CD19, CD7, and CD70) are under investigation. Here, CD38 is linked to acute myeloid leukemia.